Our Pricing

How Long Do You Take Wegovy For Weight Loss?

Published on: June 03, 2026

Understanding how long do you take Wegovy for weight loss is essential before starting treatment. Most patients use Wegovy for a minimum of 12 months to achieve and maintain clinically significant weight reduction, though many continue long-term under prescriber supervision. At Cured Pharmacy, our UK-registered clinical team provides ongoing support throughout your weight management journey, with Wegovy available from £79.00 following a free online consultation.

How Long Do You Take Wegovy for Weight Loss: Clinical Evidence

The STEP clinical trial programme, which led to Wegovy's UK licensing by the MHRA, tracked patients for 68 weeks (approximately 16 months) and demonstrated sustained weight reduction throughout this period [1]. Participants who completed the full treatment duration achieved an average 14.9% body weight reduction, with most weight loss occurring during the first 60 weeks [1].

Clinical data shows that Wegovy works progressively rather than immediately. The medication requires a 16-20 week dose escalation phase to reach the full 2.4mg maintenance dose, during which your body gradually adapts to semaglutide whilst appetite suppression and metabolic effects build [2]. Stopping treatment before 12 months typically means patients haven't experienced the medication's full clinical benefit.

Long-term follow-up studies indicate that weight regain commonly occurs when Wegovy is discontinued, which is why many prescribers recommend ongoing treatment for sustained weight management rather than viewing it as a short-term intervention [3]. Your UK prescriber will review your progress at regular intervals to determine the optimal treatment duration for your individual circumstances.

Wegovy Dosing Schedule and Treatment Phases

Wegovy treatment follows a structured escalation protocol designed to minimise gastrointestinal side effects whilst building therapeutic efficacy. The standard UK dosing schedule begins at 0.25mg weekly for four weeks, then increases monthly through 0.5mg, 1mg, and 1.7mg doses before reaching the 2.4mg maintenance dose at week 17 [2].

This gradual escalation isn't optional—it's a clinical requirement that significantly reduces the risk of nausea, vomiting, and treatment discontinuation. Patients who attempt to accelerate the schedule typically experience more pronounced side effects and higher dropout rates [2].

Once you reach the 2.4mg maintenance dose, most patients continue at this level indefinitely, subject to ongoing prescriber review. Some individuals may require dose adjustments based on tolerability or clinical response, but the maintenance phase typically represents the remainder of your treatment duration, whether that's 12 months, 24 months, or longer [3].

What Happens During the Maintenance Phase

The maintenance phase begins once you've completed dose escalation and stabilised on 2.4mg weekly injections. During this period, weight loss typically continues at a slower rate than the initial months, and the focus shifts toward weight maintenance and preventing regain. Clinical trials showed that patients who remained on Wegovy during the maintenance phase maintained their weight loss, whilst those switched to placebo regained approximately two-thirds of their lost weight within one year [3].

How Long Should You Stay on Wegovy for Optimal Results

NICE guidance and clinical consensus suggest a minimum treatment duration of 12 months for patients who tolerate Wegovy and demonstrate clinical response, defined as at least 5% body weight reduction after 12 weeks on the maintenance dose [4]. However, optimal duration varies significantly between individuals based on weight loss goals, metabolic health improvements, and individual response.

Many patients continue Wegovy beyond the initial 12 months, particularly those managing obesity as a chronic condition rather than targeting a specific weight goal. Long-term data from extension studies tracking patients for up to 104 weeks (two years) show sustained weight reduction and metabolic benefits without significant safety concerns during extended use [3].

Your UK prescriber will assess several factors when determining your treatment duration: rate of weight loss, achievement of clinical targets, improvement in obesity-related comorbidities such as type 2 diabetes or hypertension, tolerability of side effects, and your personal weight management goals. Treatment is typically continued as long as you're experiencing clinical benefit and tolerating the medication appropriately.

When Prescribers May Recommend Stopping Wegovy

Discontinuation may be considered if you haven't achieved at least 5% weight reduction after six months on the maintenance dose, if you experience intolerable side effects that don't improve with dose adjustment, if you've reached and maintained your target weight for an extended period with established lifestyle changes, or if medical contraindications develop during treatment. These decisions are always made collaboratively between you and your prescriber rather than following a fixed timeline.

Wegovy vs Other Weight Loss Treatments: Duration Comparison

Treatment duration expectations differ across weight loss medications licensed in the UK. Saxenda (liraglutide), an older GLP-1 receptor agonist requiring daily injections, typically follows similar long-term use principles to Wegovy, though clinical trials were shorter in duration and showed lower average weight reduction [5].

Orlistat, a lipase inhibitor available both on prescription and over the counter, is generally used for shorter durations of 6-12 months alongside dietary fat restriction. Unlike Wegovy, Orlistat works mechanically rather than hormonally and doesn't carry the same expectation of long-term use for weight maintenance [4].

Mounjaro (tirzepatide), the newest weight loss injection licensed in the UK, demonstrated even greater weight reduction than Wegovy in head-to-head trials, with treatment durations in clinical studies extending to 72 weeks [6]. Like Wegovy, tirzepatide is increasingly recognised as a long-term treatment rather than a temporary intervention.

What to Expect When Stopping Wegovy Treatment

Clinical evidence clearly demonstrates that weight regain is common after discontinuing Wegovy, even in patients who achieved significant weight loss during treatment. The STEP 4 withdrawal trial showed that participants who stopped Wegovy after 20 weeks of treatment regained approximately 6.9% of their body weight over the following 48 weeks, whilst those who continued treatment maintained their weight loss [3].

This weight regain occurs because semaglutide's appetite-suppressing and metabolic effects diminish once the medication clears from your system, which takes approximately 5-7 weeks given its long half-life. Without the medication's influence on GLP-1 receptors, hunger signals and metabolic rate tend to return toward pre-treatment levels unless substantial lifestyle modifications have been established and maintained [3].

If you and your prescriber decide to discontinue Wegovy, gradual dose reduction isn't typically necessary from a safety perspective, though some clinicians prefer a stepwise approach to help patients psychologically adjust. The focus should shift entirely to sustainable dietary patterns, regular physical activity, behavioural strategies, and potentially other weight management interventions to minimise regain. Regular follow-up with your healthcare team remains important during this transition period.

Strategies to Maintain Weight Loss After Stopping

Successful weight maintenance after discontinuing Wegovy requires establishing sustainable habits during treatment rather than relying solely on the medication's effects. Evidence-based strategies include maintaining a structured eating pattern with regular meal times, continuing food tracking or mindful eating practices developed during treatment, prioritising protein intake to preserve muscle mass and satiety, engaging in at least 150-300 minutes of moderate physical activity weekly, and maintaining regular weight monitoring to detect early regain. Some patients transition to other weight management medications or interventions rather than stopping treatment entirely.

Getting Started with Wegovy at Cured Pharmacy

At Cured Pharmacy, we understand that how long do you take Wegovy for weight loss is just one of many questions you'll have before starting treatment. Our UK-registered clinical team, led by Superintendent Pharmacist Tarun Kumar (GPhC 2233073), provides comprehensive support throughout your entire treatment journey, from initial consultation through dose escalation and long-term maintenance.

Your journey begins with a free online clinical assessment taking under three minutes, during which a UK prescriber reviews your medical history, current medications, weight loss goals, and suitability for Wegovy. If approved, your prescription is dispensed from our GPhC-registered pharmacy (9012511) and delivered in 100% discreet packaging directly to your door.

We offer transparent upfront pricing with Wegovy available from £79.00 per month, significantly lower than typical UK market rates. Unlike some providers, you'll see exact costs before completing your consultation, with no hidden fees or surprise charges. Our team remains available on (+44) 116 4646009 throughout your treatment for clinical questions, dose escalation guidance, or side effect management. Whether you use Wegovy for 12 months, 24 months, or longer, we're here to support your weight management success with genuine UK-licensed medication and expert pharmaceutical care.

Scientific References

1. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
2. Novo Nordisk. (2023). Wegovy 2.4 mg Solution for Injection in Pre-filled Pen: Summary of Product Characteristics. Electronic Medicines Compendium. Retrieved from https://www.medicines.org.uk/emc/product/13799 [accessed 13 August 2026]
3. Rubino, D., Abrahamsson, N., Davies, M., et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 325(14), 1414–1425. https://doi.org/10.1001/jama.2021.3224 [accessed 13 August 2026]
4. National Institute for Health and Care Excellence. (2023). Semaglutide for Managing Overweight and Obesity. NICE Technology Appraisal Guidance [TA875]. Retrieved from https://www.nice.org.uk/guidance/ta875 [accessed 13 August 2026]
5. Pi-Sunyer, X., Astrup, A., Fujioka, K., et al. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, 373(1), 11–22. https://doi.org/10.1056/NEJMoa1411892 [accessed 13 August 2026]
6. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
7. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
8. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
9. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary, and weight loss outcomes depend on multiple factors including adherence to treatment, lifestyle modifications, and individual metabolic response.